1. Home
  2. BBWI vs LQDA Comparison

BBWI vs LQDA Comparison

Compare BBWI & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bath & Body Works Inc.

BBWI

Bath & Body Works Inc.

N/A

Current Price

$21.40

Market Cap

3.8B

ML Signal

N/A

LQDA

Liquidia Corporation

N/A

Current Price

$57.57

Market Cap

4.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BBWI
LQDA
Founded
1963
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.8B
4.0B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
BBWI
LQDA
Price
$21.40
$57.57
Analyst Decision
Hold
Buy
Analyst Count
18
8
Target Price
$24.93
★ $63.88
AVG Volume (30 Days)
★ 6.0M
3.1M
Earning Date
11-19-2026
11-10-2026
Dividend Yield
★ 3.79%
N/A
EPS Growth
N/A
★ 51.81
EPS
★ 1.49
N/A
Revenue
★ $7,291,000,000.00
$158,320,000.00
Revenue This Year
N/A
$379.72
Revenue Next Year
$1.69
$17.90
P/E Ratio
$14.18
★ N/A
Revenue Growth
N/A
★ 1031.18
52 Week Low
$14.28
$22.31
52 Week High
$24.94
$93.61

Technical Indicators

Market Signals
Indicator
BBWI
LQDA
Relative Strength Index (RSI) 53.15 67.76
Support Level $17.60 $53.06
Resistance Level $23.86 $63.46
Average True Range (ATR) 0.82 3.42
MACD -0.25 2.35
Stochastic Oscillator 11.69 91.35

Price Performance

Historical Comparison
BBWI
LQDA

About BBWI Bath & Body Works Inc.

Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 4% of sales from international markets in fiscal 2025. For fiscal 2025, 77% of sales stemmed from the brick-and-mortar network of more than 1,900 retail stores, similar to 2024 levels, as consumer shopping patterns remained normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like lip.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.

Share on Social Networks: